Journal
THESCIENTIFICWORLDJOURNAL
Volume 11, Issue -, Pages 320-339Publisher
HINDAWI LTD
DOI: 10.1100/tsw.2011.22
Keywords
adenosine; A(2A) adenosine receptor; inflammation; immunity; ischaemia-reperfusion; nuclear factor KB (NFKB); janus kinase (JAK); signal transducer and activator of transcription (STAT)
Categories
Funding
- British Heart Foundation
- Chest Heart and Stroke Scotland
- U.K. Biotechnology and Biological Sciences Research Council
- British Heart Foundation [PG/08/125/26415] Funding Source: researchfish
- Chest Heart and Stroke Scotland [Res10/A131] Funding Source: researchfish
Ask authors/readers for more resources
The production of adenosine represents a critical endogenous mechanism for regulating immune and inflammatory responses during conditions of stress, injury, or infection. Adenosine exerts predominantly protective effects through activation of four 7-transmembrane receptor subtypes termed A(1), A(2A), A(2B), and A(3), of which the A(2A) adenosine receptor (A(2A)AR) is recognised as a major mediator of anti-inflammatory responses. The A(2A)AR is widely expressed on cells of the immune system and numerous in vitro studies have identified its role in suppressing key stages of the inflammatory process, including leukocyte recruitment, phagocytosis, cytokine production, and immune cell proliferation. The majority of actions produced by A(2A)AR activation appear to be mediated by cAMP, but downstream events have not yet been well characterised. In this article, we review the current evidence for the anti-inflammatory effects of the A(2A)AR in different cell types and discuss possible molecular mechanisms mediating these effects, including the potential for generalised suppression of inflammatory gene expression through inhibition of the NF-KB and JAK/STAT proinflammatory signalling pathways. We also evaluate findings from in vivo studies investigating the role of the A(2A)AR in different tissues in animal models of inflammatory disease and briefly discuss the potential for development of selective A(2A)AR agonists for use in the clinic to treat specific inflammatory conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available